AbbVie (NYSE:ABBV), a United States-based biopharmaceutical company, has reported its financial results for the second quarter ended 30 June 2020, it was reported on Friday.
The firm posted net revenues of USD10.425bn in the second quarter of 2020, up 26.3% compared to the year-ago period of USD8.255bn.
The company reported a net earnings loss of USD739m, diluted loss per share of USD0.46 on a GAAP Basis and an adjusted diluted EPS of USD2.34 in Q2 2020 compared with net earnings loss of USD741m, diluted loss per share of USD0.49 on a GAAP Basis and an adjusted diluted EPS of USD2.26 in Q2 2019.
Bruker Corporation to acquire ELITechGroup for EUR870m, strengthening MDx portfolio
Perrigo announces quarterly dividend increase
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva
Biosenic finalises agreement with Phebra for oral arsenic troxide development